CYP2D6 testing for breast cancer patients: is there more to the story?

Oncology (Williston Park). 2009 Dec;23(14):1236, 1243, 1249.

Authors

N Lynn Henry¹, Daniel F Hayes, James M Rae

Affiliation

¹ Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School, USA.

PMID: 20120836

No abstract available

Publication types

Comment

MeSH terms

Biomarkers
Breast Neoplasms / drug therapy*
Chemotherapy, Adjuvant
Cytochrome P-450 CYP2D6 / genetics*
Drug Incompatibility
Female
Humans
Medication Adherence
Polymorphism, Single Nucleotide / genetics
Precision Medicine*
Selective Estrogen Receptor Modulators / metabolism*
Selective Estrogen Receptor Modulators / therapeutic use
Tamoxifen / analogs & derivatives*
Tamoxifen / metabolism*
Tamoxifen / therapeutic use

Substances

Biomarkers
Selective Estrogen Receptor Modulators
Tamoxifen
4-hydroxy-N-desmethyltamoxifen
Cytochrome P-450 CYP2D6